dc.contributorUniversidade Federal do Rio Grande do Norte (UFRN)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T15:25:30Z
dc.date.accessioned2022-10-05T16:33:44Z
dc.date.available2014-05-20T15:25:30Z
dc.date.available2022-10-05T16:33:44Z
dc.date.created2014-05-20T15:25:30Z
dc.date.issued2002-01-01
dc.identifierJournal of Trace Elements In Medicine and Biology. Jena: Urban & Fischer Verlag, v. 16, n. 2, p. 69-73, 2002.
dc.identifier0946-672X
dc.identifierhttp://hdl.handle.net/11449/35919
dc.identifier10.1016/S0946-672X(02)80031-1
dc.identifierWOS:000177406700001
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3907749
dc.description.abstractDopamine (DA) and zinc (Zn++) share common mechanisms in their inhibition of prolactin (PRL) secretion. Both substances are present in the same brain areas, where Zn++ is released together with DA, suggesting a modulatory effect of Zn++ on dopaminergic receptors. The aim of the present study was to evaluate the effect of Zn supplementation on basal and PRL secretion stimulated by metoclopramide (MCP), a dopaminergic antagonist. Seven healthy men were evaluated in controlled study, where MCP (5 mg) was given intravenously, before and after 3 months of oral Zn++ (25 mg) administration. Our results indicate that chronic Zn++ administration does not change basal or MCP-stimulated plasma PRL secretion suggesting that, in humans, Zn++ does not interfere on PRL secretion mediated through dopaminergic receptors.
dc.languageeng
dc.publisherUrban & Fischer Verlag
dc.relationJournal of Trace Elements In Medicine and Biology
dc.relation3.755
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectzinc supplementation
dc.subjectprolactin secretion
dc.subjectmetoclopramide
dc.subjecthealthy men
dc.titleZinc supplementation does not inhibit basal and metoclopramide-stimulated prolactinemia secretion in healthy men
dc.typeArtigo


Este ítem pertenece a la siguiente institución